Disitamab vedotin plus tislelizumab before repeat bladder surgery for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of targeted therapy (disitamab vedotin) and immunotherapy (tislelizumab) given before a repeat bladder scraping surgery (re-TURBT) for people with high-risk or very high-risk non-muscle invasive bladder cancer that has high levels of HER2 protein (2+ or 3+). The goal is to see if this approach is safe and helps reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have high-risk or very high-risk non-muscle invasive bladder cancer that has not spread into the bladder muscle.
- Your cancer cells have HER2 levels of 2+ or 3+ (which is considered high).
- You have not had previous treatment with systemic immunotherapy or antibody-drug conjugates (like the drugs in this trial).
- You are healthy enough for surgery (TURBT) and have an ECOG performance score of 0, 1, or 2 (meaning you can do daily activities).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a combination of two drugs given directly into the bladder for a type of early-stage bladder cancer that has a specific protein marker called HER2. The goal is to see if the combination helps prevent the cancer from coming back.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.